ReviewCellular and molecular neurobiology2026
Targeting Sensory Neuropathies Through Neurotrophin-Based Approaches.
Review in Cellular and molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurotrophins, including NGF, BDNF, and NT-3, are crucial regulators of neuronal survival, synaptic plasticity, and regeneration in sensory systems. Emerging evidence suggests that neurotrophin signaling may represent a common biological axis underlying both sensory neuron vulnerability and repair across auditory, visual, and olfactory systems. This review examines the roles of neurotrophins in maintaining neuronal integrity, promoting synaptic repair, and facilitating functional recovery in sensory pathways. We delved into the molecular mechanisms by which neurotrophins influence neuronal survival and plasticity, with a particular focus on cochlear synaptopathy, optic neuropathy, and olfactory dysfunction. Additionally, we compared neurotrophin-based therapies to emerging approaches, such as gene therapy, small molecules, and cell-based treatments, emphasizing their potential to complement and enhance existing strategies. Despite their therapeutic promise, several challenges persist in translating neurotrophin therapies to clinical practice, including issues related to delivery efficiency and pharmacokinetics. Overall, neurotrophin-based interventions, especially when integrated with complementary regenerative approaches, may offer an effective strategy for restoring sensory function and modifying disease progression, paving the way for future clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.